Jason P. Rhodes is Director at Dyne Therapeutics, Inc. (DYN). They have made 15 open-market trades across 4 companies since 2014, most recently 2026-08-14.
CIK 0001577014
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $35.0M since 2019, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DYN | SELL · 10b5-1 | 2026-08-13 | 2026-08-17 | $25.20 | $65.2M | +0.0% | -33.6% | — |
| DYN | SELL · 10b5-1 | 2026-07-06 | 2026-07-08 | $22.97 | $17.9M | -3.2% | +8.4% | -36.4% |
| DYN | SELL · 10b5-1 | 2026-06-26 | 2026-06-30 | $21.23 | $10.7M | +5.7% | +14.9% | -26.9% |
| DYN | SELL · 10b5-1 | 2026-06-23 | 2026-06-26 | $21.09 | $5.6M | +14.6% | +21.1% | -22.0% |
| DYN | SELL · 10b5-1 | 2026-05-04 | 2026-05-06 | $18.14 | $1.9M | -11.6% | -8.8% | +38.8% |
| DYN | SELL · 10b5-1 | 2026-04-28 | 2026-04-30 | $18.38 | $4.2M | +5.7% | +7.2% | +44.5% |
| DYN | SELL · 10b5-1 | 2026-04-23 | 2026-04-27 | $18.47 | $7.1M | -2.9% | +0.5% | +41.9% |
| DYN | SELL · 10b5-1 | 2026-04-20 | 2026-04-22 | $19.75 | $16.5M | -8.8% | -10.5% | +22.7% |
| DYN | SELL | 2024-11-14 | 2024-11-18 | $33.10 | $26K | +6.0% | -15.0% | -52.3% |
| DYN | SELL · 10b5-1 | 2024-03-01 | 2024-03-05 | $30.05 | $2.8M | +3.7% | -2.0% | +16.4% |
| DYN | SELL · 10b5-1 | 2024-02-26 | 2024-02-28 | $24.30 | $39.2M | -0.4% | +9.1% | +17.0% |
| DYN | SELL · 10b5-1 | 2024-02-21 | 2024-02-23 | $22.64 | $22.7M | +17.7% | +14.5% | +37.4% |
| DYN | SELL · 10b5-1 | 2024-02-15 | 2024-02-20 | $23.26 | $23.7M | +29.2% | +29.4% | +56.9% |
| DYN | BUY | 2022-12-12 | 2022-12-14 | $10.70 | $20.0M | -20.4% | -8.0% | -4.1% |
| GBIO | SELL | 2021-09-27 | 2021-09-29 | $25.40 | $4.1M | -9.6% | -14.7% | -68.0% |
| GBIO | SELL | 2021-09-22 | 2021-09-24 | $26.01 | $7.0M | -8.2% | -13.8% | -67.4% |
| GBIO | SELL | 2021-06-24 | 2021-06-28 | $25.85 | $1.6M | -2.8% | -19.3% | -3.0% |
| GBIO | SELL | 2021-06-21 | 2021-06-23 | $25.05 | $9.3M | -0.5% | -19.3% | +1.3% |
| GBIO | SELL | 2021-04-12 | 2021-04-14 | $25.92 | $7.3M | +40.2% | +18.6% | -14.2% |
| GBIO | SELL | 2021-04-07 | 2021-04-09 | $28.20 | $7.2M | +16.4% | +11.3% | -6.4% |
| REPL | SELL | 2021-01-26 | 2021-01-28 | $46.14 | $513K | +1.8% | -12.5% | -13.5% |
| REPL | SELL | 2020-12-18 | 2020-12-22 | $41.95 | $308K | -1.9% | +13.2% | -12.4% |
| REPL | SELL | 2020-12-15 | 2020-12-17 | $42.30 | $4.5M | +2.4% | +3.2% | -15.8% |
| REPL | SELL | 2020-12-10 | 2020-12-14 | $43.34 | $8.7M | -5.0% | -1.8% | -22.8% |
| REPL | SELL | 2020-12-07 | 2020-12-09 | $45.93 | $19.8M | -7.0% | -0.9% | -23.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.